Here, we use a vaccine consisting of DNA priming followed by MVA boosting in rhesus macaques to investigate the ability of GM-CSF DNA to serve as an adjuvant for the elicitation of neutralizing Ab against an HIV-1 Env. The trial used Gag, Pol, and Env sequences from SHIV-89.6 in the immunogens and a neutralization escape variant of SHIV-89.6, SHIV-89.6P, for challenge. Co-delivery of GM-CSF and vaccine DNAs enhanced the temporal appearance of neutralizing Ab and broadened the specificity of the neutralizing activity to include SHIV-89.6P. Two longterm SHIV-89.6 infections elicited neutralizing activity for SHIV-89.6 but not SHIV-89.6P. Studies on the avidity of the anti-Env antisera revealed that the GM-CSF-adjuvanted vaccine had elicited higher avidity Ab than the non-adjuvanted vaccine or the infection. The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the nonadjuvanted group.
Introduction
Recently, good progress has been made on the development of HIV/AIDS vaccines that elicit high frequencies of anti-viral T cells (Letvin, 2005; Robinson, 2002) . In preclinical models, these vaccines prevent disease by controlling infections. In order to prevent infection, HIV/AIDS vaccines will need to elicit neutralizing Ab capable of blocking infections before they establish latency. Neutralizing antibodies capable of blocking primary isolates of HIV-1 have proven difficult to generate due to the selection of these proteins for neutralization resistance. The envelope glycoproteins (Env) of HIV-1 are heavily glycosylated and conceal conserved receptor and co-receptor binding sites under loops of highly variable sequences (Burton, 1997; Kwong et al., 2002; Wyatt et al., 1998) . In natural HIV infections, the first neutralizing antibodies are directed against variable loop sequences and typically recognize the infecting virus, but not other isolates of HIV-1 (Etemad-Moghadam et al., 1998; Richman et al., 2003; Wei et al., 2003) . With time, neutralizing antibodies with activity for other isolates of HIV-1 can appear (Carotenuto et al., 1998; Moog et al., 1997; Pilgrim et al., 1997) . Monoclonal antibodies representing this broader activity target conserved neutralization domains such as the CD4 binding site, the CD4-induced co-receptor binding site, Virology 352 (2006) 285 -294 www.elsevier.com/locate/yviro and a conserved region of gp41 (Burton et al., 2005; Wyatt et al., 1998; Zolla-Pazner, 2004) . One monoclonal has been found that targets a glycosyl group and neutralizes by coating virus particles (Calarese et al., 2003) .
A unifying characteristic for all neutralizing antibodies is their affinity. Broadly neutralizing monoclonal Ab have good affinities (∼1 nM) that allow them to out-compete cellular receptors for Env binding (Parren et al., 1998) . Low affinity monoclonal antibodies with similar target specificities fail to block infections because sufficient titers of Ab cannot be achieved to compete with receptor binding. The 2G12 monoclonal Ab against glycosyl groups has good affinity (2.5 nM). Its ability to coat a virus particle presumably contributes to its ability to neutralize and opens the possibility that other high affinity Ab capable of coating the native forms of virus particles could be neutralizing (Parren and Burton, 2001) . In simian models of immunodeficiency virus infections, the appearance of neutralizing Ab capable of blocking heterologous infections correlates with the avidity maturation of the Ab response (Clements et al., 1995; Cole et al., 1997) .
In this study, we investigate the ability of granulocytemacrophage-colony stimulating factor (GM-CSF) DNA to serve as an adjuvant for enhancing anti-Env Ab responses elicited by a vaccine that consists of DNA priming and MVA boosting (DNA/MVA) (Amara et al., 2001) . In mouse models, the use of GM-CSF DNA as an adjuvant for DNA vaccines has consistently enhanced antibody and CD4 T cell responses (Barouch et al., 2002; Geissler et al., 1997; Kamath et al., 1999; Lee et al., 1998; Pasquini et al., 1997; Sin et al., 1998; Wei et al., 2003; Weiss et al., 1998; Xiang and Ertl, 1995) . The mechanisms for enhancing Ab responses are not understood. However, it is known that the co-administration of GM-CSF DNA with a DNA vaccine recruits and stimulates the maturation of antigen-presenting cells (Haddad et al., 2000; McKay et al., 2004) .
In primate models, GM-CSF DNA has had more modest effects than in mouse studies. Studies in rhesus suggest the elicitation of increased levels of malaria-specific Ab following addition of GM-CSF DNA or GM-CSF protein to DNA vaccines but limited changes in T cell responses . Immunizations combining GM-CSF, IL-4, and TNF-α DNAs further increased Ab responses over responses obtained with GM-CSF DNA alone (Rogers et al., 2002) . In humans, in a study in which Ab responses were not measured, the addition of GM-CSF DNA to malaria DNAs appeared to reduce the frequency of volunteers scoring for CD8 T cells but have no effect on CD4 T cell responses (Wang et al., 2005) .
Here, we study the effect of GM-CSF DNA on Ab responses to the HIV Env using chimeras of simian and human immunodeficiency viruses in which the Env is derived from HIV-1. The studies include analysis for effects during immunization as well as post-challenge. Our trial uses Gag, Pol, and Env sequences from SHIV-89.6 for immunization and SHIV-89.6P for challenge (Karlsson et al., 1997; Reimann et al., 1996a Reimann et al., , 1996b . SHIV-89.6P is a pathogenic neutralization escape mutant, which emerged during serial passage of the nonpathogenic SHIV-89.6 in macaques (Montefiori et al., 1998; Reimann et al., 1996a) . The 89.6P Env differs from the 89.6 Env by 12 amino acids in the extracellular domains of gp120 and gp41 (Karlsson et al., 1997) . These amino acid differences result in the 89.6P Env being highly fusogenic and causing the rapid decline of CD4 T cells in infected animals (EtemadMoghadam et al., 2001) . Although the SHIV-89.6P Env can exhibit dual tropism in in vitro studies, it preferentially uses the CXCR-4 co-receptor present on naive CD4 T cells in infected macaques (Cheng et al., 1993) . Both SHIV-89.6 and SHIV-89.6P are like incident infections in humans in eliciting typespecific neutralizing Ab early after infection (Richman et al., 2003; Wei et al., 2003) . Their overall susceptibility to neutralization by heterologous sera from infected patients is similar to that for typical incident strains of clade B HIV-1 (Li et al., 2005 ) (L. Lai, D. Montefiori, and H. Robinson, work in progress) .
Results

Vaccine trial and T cell responses
To test the adjuvant activity of GM-CSF for our Gag-PolEnv DNA/MVA vaccine, macaques were immunized at 0 and 8 weeks by single intradermal saline deliveries of 0.25 mg of a SHIV-89.6 Gag-Pol-Env-expressing DNA (DNA/89.6) in the presence or absence of 0.25 mg of a rhesus macaque GM-CSFexpressing DNA (Fig. 1A) . At 24 weeks, both groups were boosted in the absence of GM-CSF with 2 × 10 8 pfu of a SHIV-89.6 Gag-Pol-Env-expressing MVA (MVA/SHIV-89.6). The virulent SHIV-89.6P challenge was administered intrarectally at 7 months after the MVA boost. Sera and peripheral blood mononuclear cells were collected throughout the immunization and post-challenge periods to monitor immune responses. The temporal frequencies of ELISPOTS peaked after the MVA boost and then again after the challenge, similar to previously reported findings (Amara et al., 2001) . The GM-CSFadjuvanted group showed a trend toward lower frequencies of IFN-γ ELISPOTs than in the non-GM-CSF group (Fig. 1B) . This trend, however, was not significant.
In contrast to the T cell responses, the GM-CSF did affect the anti-Env Ab responses (Fig. 2) . DNA immunizations, with or without GM-CSF, did not elicit detectable levels of SHIVspecific antibodies (data not shown). However, the inclusion of GM-CSF in the priming immunizations increased the titers of anti-Env Ab raised by the MVA boost. Binding antibody for Env was detected immediately post the MVA boost in all 6 of the animals receiving GM-CSF adjuvanted DNA immunizations, but in only one of the six animals receiving nonadjuvanted immunizations (Fig. 2) .
Studies on neutralizing Ab and the post-challenge anamestic Ab response Neutralizing Ab was studied both during the immunization phase of the trial and during the anamnestic Ab response that occurred in the 1st 5 weeks post-challenge (Fig. 3) . During the immunizations, neutralizing antibodies required more time than binding Ab to appear and were first detected in the GM-CSF-adjuvanted group at the prechallenge bleed (Fig. 3A) . Unexpectedly, this neutralizing activity, while of low titers, was effective not only against the homologous SHIV-89.6, but also the neutralization escape variant, SHIV-89.6P. Neutralizing antibodies for SHIV-89.6 and SHIV-89.6P were detected in each of the 5 tested animals from the GM-CSF-adjuvanted group but were not detected in the six animals that did not receive the GM-CSF adjuvant. Vaccine-elicited neutralizing antibodies also have not been detected in 26 other animals receiving our non-adjuvanted DNA/MVA SHIV-89.6 vaccine (Amara et al., 2001; Buge et al., 2003) .
Post-challenge, comparison of the anamnestic responses in the plus and minus GM-CSF groups revealed similar temporal patterns for binding Ab, but different temporal patterns for neutralizing Ab (Fig. 3B) . In both groups, the anamnestic response for binding Ab peaked by 5 weeks post-challenge. In contrast, peak titers of neutralizing Ab for SHIV-89.6P occurred at 5 weeks post-challenge in the plus GM-CSF group, but at 12 weeks post-challenge in the minus GM-CSF group. Thus, the GM-CSF appeared to have primed an Ab response capable of neutralizing SHIV-89.6P.
Next, sera from two macaques that had been infected for 3.8 years with SHIV-89.6 were tested for neutralizing Ab. Consistent with prior trials, these sera exhibited good neutralizing activity for SHIV-89.6 but failed to neutralize SHIV-89.6P, suggesting that the GM-CSF-adjuvanted vaccine had primed neutralizing Ab with greater breadth than elicited by SHIV-89.6 infection.
Further studies on neutralizing Ab
A screen for neutralizing activity against a panel of primary isolates revealed that the DNA/MVA immunizations had primed neutralizing activity that extended to one isolate that is highly sensitive to neutralization: HIV-1-SF-162 and a 2nd isolate that has intermediate sensitivity, HIV-1-BX-08. These responses were low prior to challenge (<100) but underwent strong anamnestic responses post-challenge. The limited remaining sera and plasma for the vaccine groups were pooled, blinded, the IgG purified, and neutralization tests confirmed. The purified IgG from the post-challenge response in the two vaccine groups neutralized SHIV-89.6P, SF-162, and BX-08 (Fig. 4) . Consistent with the temporal postchallenge appearance of neutralizing Ab for SHIV-89.6P (Fig.  3B) , the plus GM-CSF group achieved 50% neutralization of SHIV-89.6P with lower amounts of IgG than the minus GM-CSF group. Also consistent with the neutralization assays using sera, the purified IgG from the SHIV-89.6 infected animal neutralized SF-162 but not BX-08 or SHIV-89.6P.
Assays for avidity maturation of the Ab response
Assays were next undertaken to test whether GM-CSF had served as an adjuvant for the avidity maturation of the anti-Env Ab response and whether the vaccines were raising higher avidity Ab than the infection (Fig. 5) . The avidity assays used ELISAs to measure the ability of the chaotropic agent NaSCN to displace IgG from a secreted oligomeric form of the 89.6 Env (89.6 gp140). Avidity assays were conducted on IgG that had been titrated in a standard ELISA to identify a dilution that scored near the high end of the linear portion of the binding curve. The end point for the assay was the molarity of NaSCN required to achieve a 50% reduction in the optical density reading for bound anti-Env Ab (for example of an assay, see Fig. 5A ).
The avidity assays revealed anti-Env Ab undergoing avidity maturation over time (Fig. 5B) . The anti-Env Ab elicited by the GM-CSF-adjuvanted vaccine achieved the highest avidity and the Ab elicited by the non-adjuvanted vaccine, the 2nd highest avidity. The SHIV-89.6 infection elicited the lowest avidity Ab (Fig. 5B) . At early points in the vaccine trial, or post-infection, 50% dissociation of the anti-Env Ab was achieved by <1 M concentrations of NaSCN. However, by the time of challenge and at 5 weeks post-challenge, anti-Env Ab in both the plus and minus GM-CSF vaccine groups required 2-2.5 M NaSCN for 50% displacement (Fig. 5B) . In contrast, at 3.8 years postinfection, the SHIV-89.6-elicited Ab required only 1.7 M NaSCN for 50% displacement. 
Control of the SHIV-89.6P challenge
The GM-CSF-adjuvanted vaccine controlled the mucosally delivered challenge infection better than the non-adjuvanted vaccine (Fig. 6) . At 2 weeks post-challenge, there was a trend for better control. The geometric mean for the peak titer of plasma viral RNA in the GM-CSF-adjuvanted group (1.5 × 10 7 ) was about 4 times lower than the peak titer in the nonadjuvanted group (5.5 × 10 7 ) and 20 times lower than the 3.3 × 10 8 peak in the unvaccinated control animals (Fig. 6A ). The frequencies of infected CD4 cells had a geometric mean of 0.1% in the plus GM-CSF group, 1.0% in the minus GM-CSF group and 4% in the control group (Fig. 6B) . Between 3 and 12 weeks post-challenge, the rate and magnitude of virus control were similar in both groups (Fig. 6C) . However, between 28 and 52 weeks, the GM-CSF group showed significantly tighter control of re-emergent virus than the non-GM-CSF group (P < 0.01). Of the 6 animals in the GM-CSF group, 5 did not exhibit low level peaks of re-emergent virus while one exhibited one very low peak. In contrast, in the non-adjuvanted group, all 6 animals exhibited low peaks of re-emergent virus with the median number of peaks being 2. After 52 weeks, the non-GM-CSF group continued to show some peaks of re-emergent virus whereas the GM-CSF group continued to maintain control below our level of detection.
All of the vaccinated animals protected their CD4 T cells from the rapid loss associated with SHIV-89.6P challenge and did not exhibit disease whereas the unvaccinated controls underwent the expected rapid loss of CD4 cells and 5 of 6 succumbed to AIDS within a year of infection (Fig. 6C) . At 2 1/2 years postchallenge, the GM-CSF-adjuvanted group was entered into a CD8 depletion study (Amara et al., 2005) . The depletion resulted in the rapid re-emergence of virus, demonstrating a critical role for CD8 T cells in the continuing control of the infection. The non-GM-CSF group was euthanized at 4 years after challenge, a time at which the animals were disease-free but still suffering low frequencies of transient low levels of re-emergent virus.
Discussion
A central problem faced by HIV vaccines is the raising of neutralizing Ab for primary isolates. Here, we show that GM-CSF can serve as an adjuvant for the broadening of the neutralizing Ab response for SHIV-89.6 to its SHIV-89.6P neutralization escape variant. Consistent with prior findings, natural infection with SHIV-89.6 elicited neutralizing Ab for SHIV-89.6 but not SHIV-89.6P. Tests for neutralization of other primary isolates revealed both the GM-CSF and non-GM-CSF-adjuvanted vaccines eliciting neutralizing activity for two primary isolates: the highly sensitive HIV-1-SF-162 and the moderately sensitive HIV-1-BX-08. The SHIV-89.6 sera had a narrower neutralization potential, neutralizing only HIV-1-SF-162.
The GM-CSF-adjuvanted and non-adjuvanted vaccine groups had similar time courses for the appearance of postchallenge binding Ab, but different time courses for the appearance of neutralizing Ab for SHIV-89.6P, which appeared first in the GM-CSF-adjuvanted group. Thus, during the 8 weeks immediately post-challenge, the GM-CSF group had broader neutralizing activity per ELISA unit of anti-Env Ab than the non-GM-CSF group. Studies on the avidity of the Ab responses were consistent with the avidity of Ab for the 89.6 Env, correlating with the breadth of neutralizing activity and with the vaccine-elicited Ab undergoing better avidity maturation than the infection-elicited Ab. GM-CSF appeared to have accentuated this phenomenon, with the plus GM-CSF group having higher avidity Ab than the minus GM-CSF group. Avidity maturation of the Ab response takes place in lymph node germinal center reactions where Ab undergoes hypermutation and selection for affinity. Entry into a germinal center reaction requires conjugation of cognate CD4 T and B cells. Immunodeficiency virus infections preferentially kill anti-viral CD4 T cells (Douek et al., 2002; Horton et al., 2002) and may therefore be poor at providing CD4 help for the anti-Env Ab response. Thus, a vaccine may be able to prime both higher avidity and broader neutralizing Ab than its cognate infection by providing better CD4 T cell help for the anti-Env B cell response.
The ability of GM-CSF to augment the avidity maturation of the Ab response has been observed in this trial as well as an ongoing repeat trial (work in progress). GM-CSF recruits and stimulates the maturation of antigen-presenting cells (Haddad et al., 2000) . In macaques and humans, dendritic cells differentiate into at least two major lineages: plasmacytoid and myeloid (Ardavin et al., 2001; Coates et al., 2003; Shortman and Liu, 2002) . These lineages differ in their ability to produce TNF-α (plasmacytoid) and IL-12 (myeloid). In mice, GM-CSF favors the elicitation of dendritic cells that produce IL-4 and IL-10 ( Daro et al., 2000) . The types of dendritic cells expanded in macaques have not been defined. For example, avidity maturation of the Ab response could be favored by GM-CSF preferentially eliciting dendritic cells that favor CD4 T cell trafficking to germinal centers. Such T cells are designated T FH and display the CXCR5 chemokine receptor (Breitfeld et al., 2000; Mackay, 2000; Schaerli et al., 2000) . GM-CSF might also affect Ab responses by influencing the ability of dendritic cells to traffic to germinal centers for local antigen presentation and stimulation of B cell responses.
In addition to fostering the neutralizing activity of the antiEnv Ab responses, the GM-CSF adjuvant also improved the long-term control of the post-challenge infection as measured by the frequency of low level peaks of re-emergent virus (P < 0.01). In our ongoing repeat experiment, GM-CSF has again fostered better control of the SHIV-89.6P challenge, reducing peak as well as early set point viremia by 10-fold. In the repeat trial, additional MVA boosts supported the maturation of neutralizing Ab for SHIV-89.6P in the minus GM-CSF group and both groups underwent similar post-challenge expansions of neutralizing Ab for SHIV-89.6P. Again, the GM-CSF adjuvant did not increase ELISPOT responses in PBMC. Thus, we have reproducibly found higher avidity Ab and better protection for the GM-CSF-adjuvanted vaccine, but do not have SHIV-89.6P neutralizing Ab as a clear correlate for this improved protection.
Materials and methods
Immunogens
The construction and production of DNA and MVA immunogens have been previously described (Amara et al., 2001 ). The SHIV-89.6 DNA (DNA/89.6) expressed Gag, Pol, Env, Tat, Rev, Vif, Vpr, and Vpu using the pGA expression vector. This expression vector uses sequences from the CMV immediate early gene as a promoter and sequences from the bovine growth hormone polyadenylation sequence for termination. The MVA (MVA/89.6) expressed SHIV-89.6 Gag, Pol, and Env using a synthetic early/late promoter and insertion sites III and II, respectively (Amara et al., 2001) . The 89.6 Env protein in the MVA was truncated for the COOH-terminal 115 amino acids of gp41. A rhesus macaque GM-CSF DNA provided by the Resource for Nonhuman Primate Reagents (Emory University) was expressed by subcloning the gene with its signal sequence in the pGA expression vector (Hutchinson et al., 2001 ).
Immunizations and challenge
Young adult rhesus macaques from the Yerkes breeding colony were cared for under guidelines established by the Animal Welfare Act and the NIH "Guide for the Care and Use of Laboratory Animals" using protocols approved by the Emory University Institutional Animal Care and Use Committee. All vaccinated animals received a single inoculation of 0.25 mg of DNA/89.6 intradermally at 0 and 8 weeks and 2 × 10 8 pfu of MVA/SHIV-89.6 delivered both intradermally and intramuscularly at 24 weeks. The GM-CSF-adjuvanted group received 0.25 mg of DNA expressing macaque GM-CSF mixed with 0.25 mg of DNA/89.6 as single intradermal inoculations at weeks 0 and 8. Control animals received vector DNA without vaccine inserts at 0 and 8 weeks and MVA without an insert at 24 weeks. At 7 months after the MVA, booster animals received an intrarectal challenge with SHIV-89.6P using a pediatric feeding tube to introduce 20 intrarectal infectious units (1.2 × 10 10 copies of SHIV-89.6P viral RNA) 15 to 20 cm into the rectum. SHIV copy number was determined using a quantitative real-time PCR as previously described (Amara et al., 2001; Hofmann-Lehmann et al., 2000) . All specimens were extracted and amplified in duplicate, with the mean result reported. Animal numbers are as follows: 13, RKw-4*; 14, 15, 16, 17, 18, 25 , RMb-5*; 26, RGy-5*; 27, RUs-4; 28, RPm-5; 29, RPs-4; 30, RKj-5; 49, REz-5*; 50, RGw-4; 51, RPa-5; 52, RQv-4*; 53, RRe-6; 54, RWe-6*. Rhesus with the A*01 allele are indicated with asterisks. Symbols used for individual macaques can be found in Fig. 2B . Some data for animals in the non-adjuvanted group are reported in Amara et al. (2001) .
Binding Ab
ELISAs for total anti-Env antibody were carried out on EIA/ RIA high binding polystyrene 96-well plates (Costar, Corning Life Sciences, Acton, MA). Standard curves were generated using goat anti-monkey IgG (Accurate Chemical and Scientific Corp, Westbury, NY) to capture rhesus IgG (Sigma, St. Louis, MO). Wells were coated overnight at 4°C with 200 ng of the capture Ab in 0.05 M carbonate buffer, pH 9.6 (carbonate buffer), blocked for 1 h at room temperature with 4% whey, 5% non-fat dry milk in PBS (blocking buffer), and then used to capture a serial 2-fold dilution series of rhesus IgG starting at 20 ng per well in PBS plus 4% whey. For test samples, wells on the same plates were coated overnight at 4°C with a secreted form of the ectodomain of the 89.6 Env (89.6 gp140) at 20 ng per well or a secreted receptor binding subunit of HIV-1-Bal (Bal gp120) (Quality Biologics, Gaithersberg, MD) at 200 ng per well in carbonate buffer and then blocked for 1 h with blocking buffer. Test sera were incubated in duplicate wells at 3-fold dilutions in PBS plus 4% whey for 1 h at room temperature. Plates were washed 6 times with PBS plus 0.05% Tween 20, and bound Ab was detected using peroxidase-conjugated goat anti-macaque IgG (Accurate Chemical and Scientific Corp, Westbury, NY) and TMB substrate (KPL, Gaithersburg, MD). Reactions were stopped with 100 μl of 2 N H 2 SO 4 . Standard curves were fitted, and sample concentrations were interpolated as μg of Ab per ml of serum using SOFTmax 2.3 software (Molecular Devices, Sunnyvale, CA).
Neutralization assays
The titers of neutralizing antibody for SHIV-89.6 and SHIV-89.6P were determined using MT-2 cell killing and neutral red staining (Montefiori et al., 1988) . Neutralization titers are the reciprocal of the serum dilution required to protect 50% of cells from the killing effects of the indicated viruses grown in human PBMC. This cut-off corresponds to an approximate 90% reduction in virus yield (Bures et al., 2000) . Neutralizing antibody assays were performed blinded. The titers of neutralizing Ab for primary isolates were determined using a luciferase reporter gene assay in 5.25.EGFP.Luc.M7 cells (Montefiori, 2004) . IgG samples were screened in endpoint assays for the concentration of serum required to achieve a 50% reduction in RLU.
Avidity assays
Avidity assays were conducted using purified IgG which had been titrated for binding Ab against 89.6 gp140 to identify concentrations giving ODs that were at the high end of the linear range for binding curves (typically an OD of 0.6 to 0.7 on a binding curve that was linear from an OD of 0.2 to 0.8). These concentrations of IgG were then tested on duplicate wells for displacement from Env during a 15-min incubation at room temperature by increasing molarities of NaSCN prepared in PBS immediately prior to use. Following the NaSCN treatment, plates were washed 6 times with PBS plus 0.05% Tween and scored for bound Ab as done in binding assays. The molarity of NaSCN required for 50% displacement of bound sera was estimated using optical densities, with the optical density of the untreated sample being considered 100%. Each plate contained a standard curve for macaque IgG to verify that the OD for untreated samples was at the high end of the linear range of the assay. Each plate also contained low and high avidity standards. The low avidity standard consisted of pooled sera from 12 weeks post-challenge from a group of macaques that had received a Gag-Pol without Env DNA/MVA vaccine (Amara et al., 2002a) . The high avidity standard was purified IgG from a group of animals that had received three MVA/SHIV-89.6 immunizations (Amara et al., 2002b) . The avidity assay was highly reproducible with standard deviations for independent determinations of <15%.
ELISPOT assays
Assays for IFN-γ ELISPOTs used pools of overlapping peptides (22 mers overlapping by 10 for Gag and 15 mers overlapping by 11 for Env) and were conducted as previously described (Amara et al., 2001 (Amara et al., , 2002b .
Statistical analyses
Antibody levels, number of infected cells, viral load, and CD4 cell counts were compared for the GM-CSF-adjuvanted group and non-adjuvanted groups at selected time points during the study. Because the data distributions were typically skewed, we used the non-parametric Wilcoxon test for independent samples. When multiple tests were computed for the same measure for different time points, the Bonferroni method was used to adjust for the multiple comparisons. A two-sided P < 0.05 was considered statistically significant. Analyses for differences in the frequency of re-emergent virus noted the number of occasions during the 6 samples obtained from weeks 28 to 70 in the trial on which each animal had detectable levels of virus. The resulting scores for the non-GM-CSF-adjuvanted group were 1, 1, 1, 3, 4, and 6 (median = 2), while the scores for the GM-CSF-adjuvanted group were 0, 0, 0, 0, 0, and 1 (median = 0). These scores were analyzed for significance using the Wilcoxon test.
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